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ABSTRACT
The ability of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating
factor (GM-CSF) administration to increase the content of blood leucocytes and hematopoietic progenitor
cells (HPCs) is well established, yet the effect of these cytokines on immune function is less well described.
Recent data indicate that plasmacytoid dendritic cells (DC2) may inhibit cellular immune response. We
hypothesized that administration of the combination of G-CSF and GM-CSF after chemotherapy would
reduce the type 2, or plasmacytoid, DC2 content of the autologous blood HPC grafts compared with treatment
with G-CSF alone. To test this hypothesis, 35 patients with lymphoma and myeloma were randomized to
receive either G-CSF or the combination of G-CSF plus GM-CSF after chemotherapy, and blood HPC grafts
were collected by apheresis. Cytokine-related adverse events between the 2 groups were similar. More than 2
 106 CD34 cells per kilogram were collected by apheresis in 14 of 18 subjects treated with G-CSF and in
16 of 17 subjects treated with GM-CSF plus G-CSF (p  not significant). There were minor differences
between the 2 groups with respect to the content of T cells and CD34 cells in the apheresis products.
However, grafts collected from recipients of the combination of GM-CSF plus G-CSF had significantly fewer
DC2 cells and similar numbers of DC1 cells compared with recipients treated with G-CSF alone. A third
cohort of patients received chemotherapy followed by the sequential administration of G-CSF and the addition
of GM-CSF 6 days later. Grafts from these patients had a markedly reduced DC2 content compared with those
from patients treated either with G-CSF alone or with the concomitant administration of both cytokines.
These data, and recent data that cross-presentation of antigen by DC2 cells may induce antigen-specific
tolerance among T cells, suggest that GM-CSF during mobilization of blood HPC grafts may be a clinically
applicable strategy to enhance innate and acquired immunity after autologous and allogeneic HPC transplan-
tation.
© 2004 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Effective immunotherapy requires the generation
f antigen-speciﬁc cellular or antibody responses that
hen initiate the effector arm of the immune system. r
48or this to occur, antigen-presenting cells must prime
and B cells with the target antigen in the appropri-
te cellular milieu required for the generation of ac-
ivated T- and B-cell responses. Dendritic cells (DCs)
egulate the initiation of innate and adaptive immune
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Mobilization of Dendritic Cell Subsets in Hematopoietic Progenitor Cell Products
Besponses and can shape T cell–mediated responses to
ntigens [1,2]. In humans, at least 2 types of DCs have
een phenotypically deﬁned and named: type 1, or
yeloid, DCs (DC1; lin/HLA-DR/CD11c/
D123dim) [3] and type 2, or lymphoid, DCs (DC2;
D4bright/lin/HLA-DR/CD11c/CD123) [4].
he functions of these 2 DC subsets are different
ecause they polarize naive T-cell responses in diver-
ent ways [5]. DC1 cells polarize naive T cells toward
T-helper (Th)1 response (secretion of interleukin
IL]–2, IL-12, and interferon [IFN]–), whereas DC2
ells polarize naive T cells toward a Th2 response
secretion of IL-4, IL-5, and IL-10) [6]. Laboratory
ata from our group and others using highly puriﬁed
uman DC subsets have further corroborated the
odel that DCs have divergent effects on T-cell po-
arization and proliferation. Puriﬁed DC1 cells are
ble to induce brisk proliferation of autologous T cells
n response to alloantigen with associated secretion of
igh amounts of IL-12. Conversely, puriﬁed DC2
ells from the same donor result in minimal prolifer-
tion of autologous naive T cells against the same
ntigen and are associated with little IL-12 secretion
unpublished data). In addition to the priming effects
f DC1 and DC2 cells, these DC subsets are also
esponsible for determining the T-cell phenotype
Th1 versus Th2) of naive T cells in this setting. Thus,
he differential effects of DC subsets (stimulatory or
olerance inducing) represent a central part of im-
une regulation and tumor escape. Additional data
rom Munn et al. [7] implicate tolerance-inducing
Cs as being required for the metastasis of in situ
umors. Despite these laboratory-based models, there
ave been few human data evaluating the effect of DC
ubsets on clinical outcomes or strategies directed at
odulating the DC content of the blood and bone
arrow.
Data published by Waller et al. [8] represent one
f the ﬁrst clinical investigations of the effect of DC
ontent on outcomes after cancer therapy. In that
xperience, allogeneic bone marrow transplant recip-
ents who received grafts containing more donor DC2
ells developed less chronic graft-versus-host disease
GVHD), had higher rates of relapse, and had poorer
vent-free survival compared with recipients who re-
eived fewer donor DC2 cells. These clinical data,
laced in the context of in vitro and animal models
emonstrating that suppressive DCs are potent inhib-
tors of T cell–mediated responses, led to the initia-
ion of a series of clinical investigations directed at
rying to modulate peripheral blood and peripheral
lood stem cell (PBSC) graft content of DC1 and
C2 cells.
Hematopoietic cytokines that act predominately
n the myeloid lineage are known to regulate the
umbers of DCs and T cells in the blood in healthy
onors [9]. Granulocyte colony-stimulating factor (G- p
B&MTSF) is a hematopoietic growth factor required for
uman DC2 development from hematopoietic pro-
enitor cells (HPCs), whereas granulocyte-macroph-
ge colony-stimulating factor (GM-CSF) is required
or the development of human DC1 cells from HPCs
10]. On the basis of these observations, we hypothe-
ized that the content of DCs in the HPC graft could
e altered by treatment with either G-CSF or GM-
SF. Because donor DCs seem to regulate the nature
f posttransplantation immune function (enhanced or
educed graft-versus-tumor effect) [8], factors such as
he hematopoietic cytokines used to mobilize HPC
rafts before collection could affect the immunother-
peutic potential of the transplantation. To test the
ifferential effects of cytokines on graft contents, we
nitiated a randomized clinical trial comparing G-CSF
ith the combination of G-CSF and GM-CSF on the
ontent of DC subsets and T-cell phenotype (as de-
ned by the intracellular cytokine expression of these
cells when exposed to T-cell mitogens) in autolo-
ous HPC grafts collected after chemotherapy mobi-
ization. Theoretically, manipulations in DC subset
ontent can have a profound effect on naive T-cell
esponses against antigens (Th1 versus Th2); thus, we
lanned to also evaluate not only the T-cell subset
ontent, but also the functional ability of mobilized T
ells collected with the different cytokine regimens.
he data from this randomized trial and a subsequent
ohort of patients treated with sequential administra-
ion of GM-CSF and G-CSF represent the ﬁrst dem-
nstration that signiﬁcant effects on the content of
C subsets in the HPC graft can be achieved by using
ifferent combinations of Food and Drug Administra-
ion–approved, commercially available cytokines.
hese results provide the basis for future studies to
valuate the effect of these different cytokine combi-
ations on graft contents, immune reconstitution,
nd, ultimately, clinical outcomes.
ATERIALS AND METHODS
Thirty-ﬁve patients between the ages of 18 and 65
ears were enrolled onto an institutional review
oard–approved study after they granted appropriate
nformed consent. Patients with lymphoma (n  12)
r multiple myeloma (n  23) who were determined
o be appropriate candidates for high-dose chemo-
herapy followed by autologous PBSC transplantation
ere randomly assigned to received either twice-daily
ubcutaneous injections of G-CSF [11] (5 g/kg twice
aily; cohort A) or daily injections of the combination
cohort B) of G-CSF (5 g/kg/d each morning) and
M-CSF (5 g/kg/d each evening) after treatment
ith cyclophosphamide 4 g/m2 (n  5; IV infusion
ver 2 hours for 1 dose), the combination of cyclo-
hosphamide 4 g/m2 and etoposide 200 mg/m2
849
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8n  28), or other chemotherapy (ifosfamide 5 g/m2
ver 24 hours on day 2, carboplatin AUC 5 on day 2,
nd etoposide 100 mg/m2/d on days 1-3 [12], n  1
ICE]; or cisplatin 25 mg/m2/d on days 1-4, etoposide
0 mg/m2/d on days 1-4, methylprednisolone 500 mg
V on days 1-4, and cytarabine 2 g/m2 on day 5 [13],
 1). Cytokines were administered on a twice-daily
chedule according to reports suggesting an improved
D34 yield when cytokines are given in this fashion
14-16] and were administered on the basis of a ﬁxed
osing algorithm until the HPC graft was successfully
ollected by apheresis (n  30) or until it was deter-
ined that insufﬁcient CD34 cells were mobilized
nto the blood for collection of an autologous HPC
raft (nonmobilizers, n  5).
Baseline characteristics were similar between the 2
roups (Table 1). All patients received antimicrobial
rophylaxis with ciproﬂoxacin, penicillin, acyclovir,
nd ﬂuconazole [17]. An aliquot of peripheral blood
btained before the administration of chemotherapy
nd an aliquot from the apheresis product obtained on
he ﬁrst day of collection were analyzed for content of
-cell, natural killer cell, DC, and stem cell subsets by
sing ﬂow cytometry [18]. Four-color ﬂow cytometry
as performed with a FACSCaliber (Becton Dickin-
on, Sunnyvale, CA). A minimum of 50 000 events
ere acquired, stored in list mode ﬁles, and analyzed
ith CellQuest software (Becton Dickinson). DC1
ere phenotypically deﬁned as lin/HLA-DR/
D11c/CD123 [3], whereas DC2 were phenotyp-
cally deﬁned as CD4bright/lin/HLA-DR/CD11c/
D123 [4].
A third cohort of patients (cohort C; n  49) who
able 1. Baseline Characteristics among the Three Treatment Cohorts
Variable Cohort A Cohort B Cohort C
otal 18 17 70
uccessfully mobilized 14 16 57
ge, y, median (range) 48 (21-60) 55 (31-67) 54 (22-76)
ex
Male 10 12 34
Female 8 5 23
isease
Myeloma 13 10 23
Lymphoma 5 7 28
herapy
Cyclophosphamide 2 3 20
Cyclophosphamide 
etoposide 15 13 2
ICE 1 15
Hyper-CVAD 6
Cytarabine based 6
Others 1 9
ohort A was randomized to receive G-CSF alone, cohort B was
randomized to receive the combination of G-CSF plus GM-
CSF, and cohort C was a subsequent series of patients who
received G-CSF followed by the combination of G-CSF plus
GM-CSF.ere mobilized with the combination of G-CSF and p
50M-CSF after chemotherapy administration also had
he DC content of the graft measured and were eval-
ated to conﬁrm the ﬁndings from the randomized
ohort. The diagnoses in this third cohort included
ymphoma (n 26) and myeloma (n 23). Cells from
single patient with non-Hodgkin lymphoma were
obilized and collected twice, and this is reported as
separate mobilization events. In this group, patients
eceived hyperfractionated cyclophosphamide, vin-
ristine, doxorubicin, and dexamethasone (CVAD)
19] (n  6), cyclophosphamide with or without eto-
oside (n 22), ICE with or without rituximab [20] (n
12), or other regimens (n  9) as therapy before
nitiation of high-dose growth factor and HPC collec-
ion. G-CSF was initiated at 5 g/kg/d 48 hours after
he completion of chemotherapy and was continued
ntil graft collection was complete. GM-CSF 5 g/
g/d was initiated on the seventh day after chemother-
py administration and was continued in combination
ith G-CSF until collection of the HPC graft by
pheresis was completed.
pheresis
Patients had daily complete blood counts begin-
ing on day 7 after the administration of chemo-
herapy, and the CD34 content of the peripheral
lood was measured once the white blood cell count
as 1.0  103/L. When the product of the white
lood cell count and the CD34 percentage in the
lood was greater than 20 L, apheresis was initiated
ntil a target of 5  106 CD34 cells per kilogram or
minimum of 2  106 CD34 cells per kilogram was
ollected. Apheresis was conducted with a Cobe
pheresis unit, and daily collection was performed
ith 18-L volumes. An aliquot of the unmanipulated
BSC graft was sent for ﬂow cytometry and for T-cell
unctional assays. For patients in the randomized trial,
7 of 30 patients underwent CD34 selection with
solex version 1.12 or 2.5 (Baxter, Chicago, IL) [21] in
n effort to reduce tumor cell contamination of the
raft.
low Analysis
Mononuclear cells in the apheresis sample were
eparated by centrifugation over Ficoll-Hypaque. The
ells were then resuspended in 100 L of staining
edia at a concentration of 1 107 cells per milliliter.
xtracellular staining was performed in a standard
ashion by using antibodies against CD3, CD4, CD8,
D11c, CD123, CD34, CD38, CD56, CD16, and
LA-DR (Becton Dickinson).
ntracellular Cytokine Analysis
Peripheral blood mononuclear cells were placed in
resh media for 16 hours with the T-cell mitogen
horbol myristate acetate (PMA)/ionomycin. A
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Mobilization of Dendritic Cell Subsets in Hematopoietic Progenitor Cell Products
Brotein transport inhibitor (GolgiStop; Pharmingen,
an Diego, CA) was added for an additional 5 hours
y using conditions speciﬁed by the supplier. Cells
ere assayed for simultaneous expression of T-cell
henotypic markers (CD3, CD4, or CD8) and intra-
ellular cytokine production (IL-2, IL-4, IL-12, IL-
0, IFN-, or tumor necrosis factor [TNF]–) with
ppropriate ﬂuorochrome-conjugated monoclonal an-
ibodies, isotype controls, and CytoFix/CytoPerm re-
gents (Pharmingen) [22]. List mode ﬁles were ac-
uired and analyzed with CellQuest software. Samples
ere considered to be positive for cytokine expression
f the frequency of positively stained cells using anti-
odies to cytokines was at least 2-fold greater than
hat of the isotype control.
ide-Effects Questionnaire
Two weeks after successful collection of the stem
ell graft, patients from the randomized trial were
dministered a questionnaire directed at determining
he side effects they may have experienced during the
dministration of cytokines before apheresis. Patients
ere queried about standard cytokine side effects,
uch as fever, chills, bone pain, and headache. Patients
ere also given the opportunity to volunteer addi-
ional side effects or toxicities that were not speciﬁ-
ally listed on the questionnaire. These data were
ndividually tabulated for each treatment arm.
tatistical Comparisons
Statistical analysis comparing data between groups
as performed with the Student t test. The SEM was
sed to represent variance from the mean in each
reatment group. Sample-size determinations for the
andomized trial were based on a baseline frequency
f DC1 and DC2 cells within the peripheral blood of
.5% with an SD equal to the mean (0.5%). We
redicted that the addition of GM-CSF to the mobi-
ization regimen would reduce the DC2 content of the
ollected graft by 50%. On the basis of these baseline
requencies and variance, a sample size of 15 patients
er arm was needed to detect the predicted reduction
able 2. Mean Percentage of T Cells, T-Cell Subsets, Dendritic Cell S
ariable
Before Mobilization
G-CSF G  GM-CSF P
DC1 0.42  0.11 0.33  0.08
DC2 0.21  0.04 0.18  0.04
CD34 0.08  0.02 0.14  0.07
CD3 22.9  2.7 17.1  2.3
CD4 10.7  1.5 8.0  1.0
CD8 11.9  2.5 9.0  1.9
alues are mean percentage 	 SEM.n DC2 content with a power of 90%. m
B&MTESULTS
Thirty-ﬁve patients were randomized to receive
ytokine mobilization with either G-CSF alone (co-
ort A; n  18) or the combination of GM-CSF plus
M-CSF (cohort B; n  17). Baseline characteristics
etween the 2 randomized cohorts (A and B) were
imilar (Table 1). HPC grafts were successfully col-
ected by apheresis from 14 of 18 patients in cohort A
nd from 16 of 17 patients in cohort B (not signiﬁ-
ant). The frequencies of T cells, DC subsets, and
D34 cells in peripheral blood before the adminis-
ration of chemotherapy were comparable between
he 2 treatment groups (Table 2). There was no dif-
erence in clinical outcomes between subjects in the 2
andomized arms, and the study was not powered to
ee a difference in progression-free survival or overall
urvival because the primary end point of the study
as graft DC content.
The percentage of DC2 cells within the apheresis
roduct was quite different between the treatment arms.
he percentage of DC2 cells from cohort B was signif-
cantly lower than that from Cohort A (0.08% versus
.26%, respectively; P .03), with no signiﬁcant change
n the percentage of DC1 cells (0.12% versus 0.19%,
espectively; P .13). There was a trend toward a higher
ercentage of CD34 cells in cohort B (3.08% G-CSF
ersus 4.89%GM-CSF plus G-CSF; P .11), but there
as no signiﬁcant difference in the percentage of T-cell
ubsets in apheresis products collected from the 2 treat-
ent arms (Table 2). When the graft cell content data
ere analyzed as a delivered cell dose per weight (num-
er of cells  106/kg), there was a signiﬁcant reduction
n the DC2 dose in the HPC grafts collected from
ubjects randomized to cohort B (GM-CSF plus G-
SF) versus patients randomized to cohort A (G-CSF
lone). The content of DC2 in the apheresis product
ollected from patients treated in cohort B was 0.20 
06/kg compared with 0.71  106/kg among patients
reated in cohort A (P  .03; Figure 1). There were no
tatistically signiﬁcant differences between numbers of
D34 cells in PBSC grafts collected after either cyto-
ine regimen (Figure 2A), but there was a trend toward
nd Stem Cells in the Peripheral Blood before Mobilization
After Mobilization
G-CSF G  GM-CSF P Value
0.19  0.04 0.12  0.02 .12
0.26  0.08 0.08  0.02 .03
3.1  0.71 4.9  1.2 .23
9.5  2.2 15.1  2.8 .14
4.8  1.5 8.1  1.2 .08
4.0  0.76 6.5  2.2 .31ubsets, a
Value
.38
.44
.21
.08
.08
.19ore T cells in grafts collected from cohort B. There
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8as no signiﬁcant difference in the DC1 content of the
raft from either randomized cytokine group (cohort A,
.77  106 DC1 per kilogram; cohort B, 0.44  106
C1 per kilogram; P  .055). There was also no differ-
nce in the number of aphereses performed in either
roup in the randomized arms of the study (median of 2
phereses for both groups).
A third cohort of patients (cohort C) received se-
uential cytokines: G-CSF followed by the addition of
M-CSF 7 days after chemotherapy mobilization. Pa-
ients in this cohort underwent a median of 2.3 collec-
ions, and a median CD34 dose of 5.8  106/kg was
ollected by apheresis. The percentage of DC subsets
ontained within the HPC grafts collected from patients
n cohort C was 0.09% for DC2 and 0.25% for DC1.
here was no signiﬁcant difference in the percentage of
C1 between cohorts A and C (0.19% versus 0.25%; P
.27), but there was a marked reduction in the percent-
ge of DC2 cells between cohorts A andC (0.26% versus
.09%; P  .06). When data were analyzed as delivered
igure 1. Dendritic cell subset content of the HPC graft repre-
ented as median cell dose  106/kg. DC subsets demonstrate
igniﬁcant reductions in the DC2 content of cohorts B and C when
ompared with cohort A.
igure 2. T-cell content, stem cell content, and DC1/DC2 ratio
PC grafts collected in cohorts A, B, and C, represented as med
hese data show marked skewing of the ratio toward DC1 cell
ompared with cohort A.
52ell dose, patients in cohort C had signiﬁcantly fewer
elivered DC2 cells (Figure 1) than those in cohort A
0.26  106 DC2 per kilogram versus 0.71  106 DC2
er kilogram; P .03), with a similar DC1 content (0.70
106 DC1 per kilogram versus 0.77  106 DC1 per
ilogram; P  .21).
When T-cell subsets were analyzed, there was an
ncrease in the percentage of CD4 cells and a trend
oward a higher percentage of CD3 cells in the grafts
ollected from cohort B (GM-CSF plus G-CSF) when
ompared with grafts collected from cohort A (G-CSF
lone; Figure 2 and Table 2). T-cell subset data demon-
trate more T cells from the grafts collected in cohort C,
oth with respect to CD4 and CD8 T cells (Figure
A). Comparing the DC1/DC2 ratio contained within
he apheresis products collected from cohorts A, B, and
, there were signiﬁcantly higher relative numbers of
C2 compared with DC1 in cohort A and signiﬁcantly
ower relative numbers of DC2 compared with DC1 in
ohorts B and C (Figure 2B). The net result was a shift
n the DC1/DC2 ratio favoring DC1 in the groups
eceiving bothG-CSF andGM-CSF. This is graphically
epresented in Figure 3, where the percentages of DC1
nd DC2 cells are plotted for each individual patient in
he analysis. Figure 3A shows the distribution of DC1
nd DC2 percentages for cohorts A and B from the
andomized trial and demonstrates that 12 of 16 patients
ho received the combination of GM-CSF/G-CSF and
nderwent apheresis tended to have more DC1 than
C2 in the HPC products with data points below the
egression line (DC1/DC2 ratio favors DC1), whereas
nly 4 of 14 patients who received G-CSF alone were
ore likely to have HPC grafts collected by apheresis
hat contained relatively more DC1 than DC2 cells and
ere below the regression line. Figure 3B demonstrates
similar plot for cohort C, who all received G/GM-
orts A, B, and C. A, T-cell subset and stem cell content of the
l dose  106/kg. B, DC1/DC2 ratio of the 3 presented cohorts.
g the recipients of both GM-CSF and G-CSF. *P 
 .05 whenof coh
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BSF, and shows a marked skewing of DC toward DC1,
ith relatively low percentages of DC2 in the apheresis
roduct.
The immune polarization status of T cells in the
pheresis products was assessed by measuring intra-
ellular cytokine expression (IL-2, IL-12, TNF-,
FN-, and IL-4) after peripheral blood mononuclear
ells from the HPC graft were activated by the non-
peciﬁc T-cell mitogen PMA. There were no signiﬁ-
ant differences in intracellular IL-2 expression
mong either CD45RA or CD45RA T cells within
ither cytokine group. There was a trend toward in-
reased IL-12 production in the group receiving the
M-CSF plus G-CSF combination of cytokines (8/11
ersus 3/6 in the G-CSF–alone arm). There were no
ifferences in IL-4, TNF-, or IFN- expression
rom T cells within the collected grafts. T cells mo-
ilized under the inﬂuence of cyclophosphamide
eemed to be globally hyporesponsive when assayed
ith intracellular cytokine expression after exposure
o the T-cell mitogen PMA, thus precluding more
xtensive cytokine studies and T-cell polarization
ata.
There were no signiﬁcant differences between the
ytokine-related side effects reported by patients be-
igure 3.DC1 and DC2 percentage in the HPC graft plotted for ea
ircles); grafts collected with G-CSF are more likely to plot above
atients randomized to receive GM-CSF plus G-CSF (cohort B) a
ontent. B, The 49 patients from cohort C, showing even further s
atio shift toward DC1 cells.ween the 2 treatment groups (Table 3). Side effects t
B&MTnd toxicity between the 2 randomized treatment arms
ere similar, and only 1 patient had to discontinue
rowth factor because of fever, chills, and myalgias in
he combination arm.
To address the effects that different mobilization
egimens may have on DC subset mobilization, we
valuated the effect of disease (myeloma, non-
odgkin lymphoma, or Hodgkin disease), chemo-
herapy (cyclophosphamide with or without etopo-
ide, ICE, hyper-CVAD, or other), or the cytokines
sed after chemotherapy on DC mobilization into the
roduct. With multivariate analysis, only the cyto-
ines used for mobilization had any effect on the
easured DC subsets within the graft. There was a
lear difference in the DC2 content of the graft when
GM-CSF was used (reduced) compared with the
rafts in which G-CSF alone was used (higher DC2
ontent). There was no signiﬁcant effect on DC1
ontent regardless of chemotherapy, disease, or cyto-
ines used for mobilization.
ISCUSSION
This randomized clinical trial was performed to
ent in all 3 cohorts. A, Cohort A (open circles) and cohort B (closed
gression line, favoring increased DC2 percentages. The group of
e likely to plot below the regression line, favoring increased DC1
of the percentages below the regression line, thus conﬁrming thech pati
the re
re mor
kewingest the hypothesis that the 2 commonly available
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8ood and Drug Administration–approved hematopoi-
tic cytokines have different effects on the mobiliza-
ion of DC subsets. We characterized the DC content
f products and evaluated the frequency of cytokine-
elated adverse events among patients randomized to
eceive G-CSF alone or in combination with GM-
SF. Our hypothesis was that GM-CSF would result
n fewer DC2 cells in the apheresis product. We were
uilding on clinical data from Arpinati et al. that
-CSF mobilizes more DC2 cells in the blood with-
ut a difference in the number of mobilized DC1 cells
nd that GM-CSF is clearly required to differentiate
uman HPCs into DC1 cells, as well as to direct
onocyte differentiation toward antigen-presenting
ells. Thus, we reasoned that cytokine combinations
hat included GM-CSF would result in fewer DC2
ells in the blood HPC graft compared with G-CSF
lone.
The results of our trial clearly demonstrated that
trategies that combined GM-CSF with G-CSF re-
uced the graft contents of DC2 cells, whether ex-
ressed as a dose per kilogram or as a percentage of
he cells in the graft. Although the absolute magnitude
f the difference in DC2 content is small (0.26%
ersus 0.08% or 0.71  106/kg versus 0.20  106/kg),
ifferences of similar magnitude were seen in the
linical article from Waller et al. [8] demonstrating
nferior survival for allogeneic bone marrow trans-
lant recipients who received grafts containing more
C2 cells (0.6  106/kg versus 0.90  106/kg). Thus,
mall differences in a cell population that is relatively
ncommon, such as DC subsets, have the potential for
profound effect on posttransplantation outcomes.
The importance of this reduction is related to the
act that DC2 cells induce naive T cells toward a Th2
henotype that may suppress antigen-speciﬁc or tu-
or-speciﬁc immunity. We did not test mobilization
ith GM-CSF alone because previous studies have
ndicated that GM-CSF alone results in mobilization
nd collection of fewer CD34 cells than do combi-
ations that include G-CSF [23]. Additionally, overall
urvival was not a study end point in this study, be-
ause most patients received HPC grafts that were
elected for CD34 progenitors, thus eliminating
ost DCs and T cells present in the graft and ren-
ering it impossible to test the effect of mobilization
ytokines on clinical outcomes in this study.
In vitro data suggest that DC subsets have diver-
able 3. Toxicity Proﬁle between the Two Randomized Treatment Arm
Cytokine Fever Bone Pain
-CSF (n  14) 4 (29) 6 (43)
 GM-CSF (n  16) 4 (25) 5 (31)
alues are the number of patients (percentage) with a given side eent functional abilities and that both DC1 and DC2 m
54ells may play a role in the initiation of antigen-
peciﬁc T-cell responses. In the context of direct and
ndirect antigen-presentation models, immature DC2
ells pulsed with antigen are much less effective at
enerating naive T-cell proliferation when compared
ith DC1 cells in the same model [9]. Ellis et al. [5]
eported a survival decrement for recipients of alloge-
eic bone marrow grafts that contained higher num-
ers of DC2 cells. On the basis of this clinical obser-
ation, we have developed in vitro models of indirect
lloantigen presentation by puriﬁed human DC1 and
C2 subsets that support our clinical observation that
C2 cells induce T-cell hyporesponsiveness. Thus,
trategies that reduce the DC2 content of the trans-
lant graft may enhance autologous antitumor immu-
ity after autologous HPC transplantation or may
nhance the graft-versus-leukemia effect in the con-
ext of allogeneic HPC transplantation.
Two strategies exist by which to modulate the
mmunotherapeutic potential of transplantation. First,
ne can use different cytokines to mobilize different
C and T-cell phenotypes in the graft, or, second,
ne can administer posttransplantation cytokines to
lter the “shape” of the DC and T-cell phenotype.
olpi et al. [24] evaluated the T-cell activation proﬁles
f de novo T cells developing after haploidentical
BSC transplantation by using the Perugia condition-
ng with stringent T-cell depletion and the absence of
osttransplantation immunoprophylaxis [24]. Their
ata demonstrated profound differences between the
mmune reconstitution of patients who received either
-CSF as the posttransplantation cytokine or no post-
ransplantation cytokine. Immune reconstitution (as
easured by CD4 count recovery) was signiﬁcantly
elayed among patients who received posttransplan-
ation G-CSF, and the T-cell activation proﬁle of
ymphocytes from patients who received posttrans-
lantation G-CSF was skewed toward a Th2 pheno-
ype (high levels of IL-4 and low levels of IL-12).
atients who received no posttransplantation cyto-
ines had more rapid immune recovery, and their
ymphocytes demonstrated a predominant Th1 phe-
otype (high IL-12 and low IL-4) [24]. More recently,
ingden et al. [26] demonstrated a survival detriment
or AML patients undergoing allogeneic transplanta-
ion who received posttransplantation G-CSF, further
upporting the point that perhaps pretransplantation
in Redness HA Other None
) 2 (14) 5 (36) 2 (14) 4 (29)
) 3 (19) 4 (25) 2 (13) 6 (38)
thin each group.s
Site Pa
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Mobilization of Dendritic Cell Subsets in Hematopoietic Progenitor Cell Products
Breferable method by which to modulate immune
unction.
To date, no large comprehensive series of patients
reated in a uniform manner with similar conditioning
nd GVHD prophylaxis has been reported to clearly
lucidate the effect of DC subsets on the events after
llogeneic PBSC transplantation or in the setting of
nmanipulated autologous PBSC transplantation.
rpinati et al. [27] recently reported that among allo-
eneic peripheral blood progenitor cell recipients, pa-
ients who received more DC2 cells had a higher
ncidence of chronic GVHD but that donor DC2
ontent had no effect on overall or progression-free
urvival. Data from the Australian transplant group
uggested an improved outcome among recipients of
llogeneic peripheral blood progenitor cell grafts con-
aining increased numbers of DC2 cells, but upon
urther analysis, this difference lost statistical signiﬁ-
ance [28]. Finally, Gladney et al. [29] reported that
ecipients of increased numbers of DC2 cells within
he peripheral blood progenitor cell graft had poorer
verall survival, but this difference did not achieve
tatistical signiﬁcance with a short follow-up. These
onﬂicting data support the need for prospective clin-
cal trials that address the importance of DCs within
he hematopoietic grafts used in transplantation.
In vitro data from our laboratory have demon-
trated that the ratio of DC1 to DC2 at the time of
ntigen presentation is an important determinant of
he polarization of immune responses after antigen
hallenge [5]. In our model, the DCs and naive T cells
re from the same normal donor, and simple depletion
f 1 DC subset allows the remaining DC subset to
redominate with respect to T-cell priming and anti-
en presentation. Additionally, it seems that this shift
n the DC ratio has the added effect of increasing
L-12 production among T cells collected in the graft.
lthough our analysis of cytokines secreted by mito-
en-stimulated T cells within the graft was limited (8
f 11 among cohort B and 3 of 6 among cohort A), our
roup and others have demonstrated that DC1 cells
rime naive T cells in a Th1 fashion, thus inducing
L-12 production. It is possible that the administra-
ion of cyclophosphamide before cytokine administra-
ion may have limited the numbers and functions of
utologous T cells collected in the apheresis products,
hus hindering our ability to show functional differ-
nces between the T cells collected with either cyto-
ine combination.
The use of G-CSF increases the number of DC2
ells and shifts the DC1/DC2 ratio in favor of DC2
ells, whereas the combination of G-CSF and GM-
SF reduces the absolute number of DC2 cells (Fig-
re 1). The net effect of GM-CSF–containing regi-
ens is reduced DC2 content, thus shifting the DC1/
C2 ratio in favor of DC1 (Figure 2B). The clinical
igniﬁcance of the DC1/DC2 ratio has not been es- h
B&MTablished, although the 2 DC subsets seem to be self-
egulatory and exist in relatively equal ratios in the
eripheral blood in healthy individuals.
An unexpected ﬁnding in our trial related to the
bsolute numbers of T cells contained within the
rafts. The numbers were comparable between the 2
andomized arms, but there was a signiﬁcantly higher
D4 and CD8 T-cell content of the grafts collected in
ohort C. This may be related to relative heterogene-
ty among the chemotherapy administered before col-
ection, as well as to a higher target CD34 dose for
he patients in cohort C with multiple myeloma. This
ncrease in T-cell content has not been seen in the
ormal donor mobilization studies by DiPersio et al.
30] or in the preliminary data from our normal donor
andomized trial, which actually demonstrated that
ormal donors receiving G-CSF plus GM-CSF had
ewer T cells in the grafts than recipients of G-CSF
lone [31].
If our hypothesis is correct (that fewer DC2 cells
n the graft will increase the overall alloreactivity),
hen a reduction in the DC2 content of the graft could
esult in prohibitively higher rates of GVHD [32].
ata from DiPersio et al. indicate that the adminis-
ration of GM-CSF plus G-CSF to healthy donors is
afe and that recipients of HPC grafts collected after
obilization with GM-CSF plus G-CSF do not ex-
erience more GVHD than a historical cohort of
atients who receive grafts collected after G-CSF
lone [30,33]; this suggests that this approach is safe.
n the setting of allogeneic peripheral blood progen-
tor cell transplantation, it has been suggested that the
ates of chronic GVHD are already higher when com-
ared with those of allogeneic bone marrow trans-
lantation and that perhaps no further enhancement
n immunity is required. Despite this change, relapse
emains the single largest cause of treatment failure
fter allogeneic HPC transplantation: this mandates
he pursuit of strategies that have the potential to
ddress enhancement of the graft-versus-tumor effect
nd overall immune reconstitution.
This study of autologous HPC mobilization col-
ected after chemotherapy and cytokine stimulation
rovides justiﬁcation for a randomized study of GM-
SF plus G-CSF versus G-CSF in allogeneic donors
ndergoing cytokine mobilization of PBSC grafts, and
his study is currently in progress [31]. The absence of
hemotherapy before cytokine mobilization should al-
ow detection of a maximal effect of the cytokine
egimen on the Th1/Th2 polarization of T cells in the
raft, as well on DC content and posttransplantation
mmune reconstitution. To our knowledge, this article
epresents the ﬁrst randomized study to test the hy-
othesis that DC subsets can be inﬂuenced by the
ytokines used for mobilization. Whether this differ-
ntial effect on DC subsets results in clinical beneﬁt
as yet to be determined. Ultimately these surrogate
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8arkers of immune function will have to be evaluated
n a randomized study in which the ﬁnal measures are
urvival, relapse, and the incidence of GVHD.
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